EMA provides new guidance on good pharmacovigilance practices

The European Medicines Agency has released new guidelines on good pharmacovigilance practices (GVP) related to pediatric populations.

The document takes into account comments received during a period of public consultation.

The EMA says its general aim in publishing GVP guidance is to prevent “harm from adverse reactions in humans arising from the use of authorized medicinal products within or outside the terms of marketing authorization or from occupational exposure.”